Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
To determine the predictive factors of a positive response to latanoprost 0.005% / timolol
0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of
treatment (age, sex, ethnic origin, patient's medical history, family history of OAG or OHT,
concomitant systemic treatment with beta-blockers, etiology, IOP at baseline, corneal
thickness, compliance, and adverse events).
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.